Haleon (LON:HLN) Given Buy Rating at Jefferies Financial Group

Haleon (LON:HLN)‘s stock had its “buy” rating reiterated by analysts at Jefferies Financial Group in a note issued to investors on Monday,London Stock Exchange reports. They presently have a GBX 440 price objective on the stock. Jefferies Financial Group’s target price would suggest a potential upside of 23.01% from the company’s previous close.

A number of other brokerages also recently commented on HLN. The Goldman Sachs Group restated a “buy” rating and issued a GBX 440 target price on shares of Haleon in a research note on Wednesday, September 10th. Berenberg Bank decreased their price target on Haleon from GBX 503 to GBX 500 and set a “buy” rating for the company in a report on Friday, August 8th. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of Haleon in a research note on Friday. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and set a GBX 370 target price on shares of Haleon in a report on Friday. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Haleon presently has a consensus rating of “Hold” and a consensus target price of GBX 437.50.

Haleon Stock Performance

Shares of LON:HLN traded up GBX 3.60 during midday trading on Monday, reaching GBX 357.70. The company’s stock had a trading volume of 13,870,658 shares, compared to its average volume of 24,095,855. The company has a quick ratio of 0.93, a current ratio of 0.84 and a debt-to-equity ratio of 53.36. The stock has a fifty day moving average of GBX 347.67 and a 200 day moving average of GBX 369.51. Haleon has a twelve month low of GBX 325.10 and a twelve month high of GBX 419.50. The firm has a market capitalization of £31.86 billion, a PE ratio of 21.42, a P/E/G ratio of 1.49 and a beta of 0.19.

Haleon (LON:HLN) last posted its quarterly earnings results on Thursday, July 31st. The company reported GBX 8.90 EPS for the quarter. Haleon had a net margin of 9.66% and a return on equity of 6.54%. On average, equities analysts expect that Haleon will post 19.5033282 EPS for the current fiscal year.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other.